The RTOG Foundation is a nonprofit organization dedicated to improving outcomes for cancer patients through the conduct of practice-changing clinical trials.
Joined March 2022
- Tweets829
- Following487
- Followers1K
- Likes421
October Webinar Registration (NEXT WEEK!): ow.ly/qwCi50ZUVxT -- #SNO2026 Investigators Meeting Registration: ow.ly/h6T750ZUVxY -- Copy of Flyer: ow.ly/ZVwo50ZUVxW
The next RO Webinar session is TOMORROW: "Therapeutic Radiopharmaceuticals: Where Specialties Combine to Bring Novel #Cancer Interventions - October 21st at 4PM ET! Register here: ow.ly/AkjC50ZIeAH
RTOG Foundation retweeted
NRG Oncology is currently accepting applications for travel awards to #NRG2027 in Las Vegas! Application window closes November 9th. More information can be found at ow.ly/oJEj50ZZ617
October is #BreastCancer Awareness Month! RTOG Foundation past publications on #BreastCancer research can be found on our website rtog.org/Clinical-Trials/Pub… as well as on the NRG website nrgoncology.org/Clinical-Tri…
October Webinar Registration: ow.ly/qVmR50ZUVnj -- #SNO2026 Investigators Meeting Registration: ow.ly/HB7950ZUVnh -- Copy of Flyer: ow.ly/5I8g50ZUVnk
Meet our 2026-2027 RTOGF Communications Interns @TugceKutukMD and @sarthakshah097 in our Fall newsletter and a special thank you to our outgoing interns, @djlee714 and @AlexisNarvaezMD for their amazing work. Read more: rtog.org/News/2026-2027-Comm…
This quarter's Investigator Spotlight is @henson_md from @StephensonCC @OUCollegeofMed We interviewed Dr. Henson on her career and accomplishments so far and her goals for her future. Read more: rtog.org/News/New-Investigat… @radonc_OU
Drs. @TugceKutukMD and @sarthakshah097 interview @NehaVapiwala on her leadership and advocacy through her career through to her recent ASTRO Presidency and ask for advice for physicians who are just getting started. Read the interview: rtog.org/News/Interview-with…
Next RO Webinar session: "Therapeutic Radiopharmaceuticals: Where Specialties Combine to Bring Novel #Cancer Interventions - October 21st at 4PM ET! Register here: ow.ly/AkjC50ZIeAH
The RTOGF Fall Newsletter is OUT! Read interviews with Drs. Vapiwala & Henson, Meet our 2026-2027 interns, and register for all the upcoming RTOG 3523 sessions: conta.cc/4ywjgct
PUB ALERT: Tocilizumab, atezolizumab, and stereotactic radiotherapy in recurrent glioblastoma: primary analysis of safety and efficacy of a phase 2 trial, NRG Oncology-BN010 - PubMed Link: pubmed.ncbi.nlm.nih.gov/4281…
PUBLICATION ALERT: NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer - Published in JCO: ascopubs.org/doi/10.1200/JCO…
Listen to The NRG Oncology Podcast discussion of the reported NRG-BR002 results published in JCO yesterday! NRGOncology.org/Podcast
With perfect timing for #BreastCancerAwarenessMonth - JCO published the results of NRG-BR002 today! Tune in as we discuss these results in newly oligometastatic #breastcancer - NRGOncology.org/Podcast
October Webinar Registration: ow.ly/qVmR50ZUVnj -- #SNO2026 Investigators Meeting Registration: ow.ly/HB7950ZUVnh -- Copy of Flyer: ow.ly/5I8g50ZUVnk
Next RO Webinar session: "Therapeutic Radiopharmaceuticals: Where Specialties Combine to Bring Novel #Cancer Interventions - October 21st at 4PM ET! Register here: ow.ly/AkjC50ZIeAH
Next week, tune in for a deeper dive of NRG-BR002 results with the NRG Oncology Podcast - NRGOncology.org/Podcast - #BreastCancerAwarenessMonth
On our first day of #BreastCancerAwarenessMonth we call to a special upcoming podcast episode on the results of NRG-BR002 being published in JCO. We dissect the results with Dr. Chmura after they are published. Check out past episodes & follow us for more: NRGOncology.org/Podcast
Check out some highlights from #ASTRO26! ⤵️
We're recapping all of the great NRG research presented at #ASTRO26 - Check it out: conta.cc/4d23LAn
#InternationalPodcastDay🎙️
RTOG Foundation retweeted
@RTOGFoundation STEEL presented by @EdwinPosadasMD and team.
Adding 24 mo enzalutamide to ADT + salvage RT improved an early PFS endpoint (HR 0.62; 80% CI 0.42–0.91), but Grade 3 AEs rose 19%→30%.
With AR signaling further suppressed, it’s unclear how much early PSA differences tell us. If 95%CI used would be non-significant even.
Need mature metastasis/clinical outcomes and ARPI doublet with SRT remains unproven. FORMULA-509 negative overall also.
#ASTRO26 @ASTRO_org @HimanshuNagarMD @rtdess @NRGonc @TylerSbrt @ndesai2005 @angela_jia_ @Soum_Roy_RadOnc
NRG press release: ow.ly/4R9650ZQHQ3 #ASTRO26 - NRG Oncology Podcast episode discussing these results: NRGOncology.org/Podcast
TODAY at #ASTRO26 do not miss the oral presentation on the RTOG 3506 STEEL study in Room 210! Session runs from 12:30-1:45PM ET.
